Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

PURPOSE: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) gefitinib and erlotinib benefit some non–small cell lung cancer (NSCLC) patients, but most do not respond (primary resistance) and those who initially respond eventually progress (acquired resistance). EGFR TKI res...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Naumov, George N., Nilsson, Monique B., Cascone, Tina, Briggs, Alexandra, Straume, Oddbjorn, Akslen, Lars A., Lifshits, Eugene, Byers, Lauren Averett, Xu, Li, Wu, Hua-kang, Jänne, Pasi, Kobayashi, Susumu, Halmos, Balazs, Tenen, Daniel, Tang, Xi M., Engelman, Jeffrey, Yeap, Beow, Folkman, Judah, Johnson, Bruce E., Heymach, John V.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2893040/
https://ncbi.nlm.nih.gov/pubmed/19447865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2904
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars